Skip to main content
Iordanis Ourailidis on Muck Rack

Iordanis Ourailidis

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Iordanis

Contact Iordanis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Correction: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples - British Journal of Cancer

|
By Markus Ball, Susanne Beck, Tina Fuchs Verified, Katja Lorenz, Alejandro Robles, Michael Allgäuer, Anna-Lena Volckmar, Iordanis Ourailidis, Regine Brandt, Petros Christopoulos, Michael Thomas, Annette Fink, Olaf Neumann, Michael Menzel, Martina Kirchner, Thoas Fioretos, Peter Schirmacher, Solange Peters, Jan Budczies, Albrecht Stenzinger, Daniel Kazdal, Darius Wlochowitz, Christiane Zgorzelski, Hannah Goldschmid, Huriye Seker-Cin, Fabian Schnecko
| Nature Verified
Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-025-03307-8, published online 14 January 2026 In this article, the author’s name, Olaf Neumann, was incorrectly written as Olaf Neuman. The original article has been corrected.
Open in Who Shared View Duplicates (4) Issue with article?

Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples - British Journal of Cancer

|
By Iordanis Ourailidis, Petros Christopoulos, Olaf Neuman, Michael Menzel, Jan Budczies, Albrecht Stenzinger
| Nature Verified
Abstract Whole Transcriptome Sequencing (WTS) is a comprehensive alternative to targeted panels for detecting gene fusions and splice variants. To integrate WTS into clinical diagnostics, we compared its performance against established fusion assays (Archer FusionPlex and TSO500 RNA). WTS was evaluated in an initial cohort of 64 FFPE tumor samples, and quality control (QC) thresholds were defined based on missed fusions correlating with low tumor cell content (TCC < 40%).
Open in Who Shared Issue with article?

Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma - npj Precision Oncology

|
By Iordanis Ourailidis, Susanne Beck, Katja Steiger, Olivier Gires, Albrecht Stenzinger
| Nature Verified
Abstract Tumor budding (TB) is a prognostic biomarker in HPV-negative and HPV-positive head and neck squamous cell carcinoma (HNSCC). Analyzing TCGA and CPTAC mutation, RNA, and RPPA data and performing proteomics and IHC in two independent in-house cohorts, we uncovered molecular correlates of TB in an unprecedentedly comprehensive manner. NSD1 mutations were associated with lower TB in HPV-negative HNSCC.
Open in Who Shared Issue with article?
See all 7 articles